Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.04.11.20062158: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization Population and study period: We included three groups of patients in our study: Group 1 (healthy controls): a randomly selected group of 55 patients who had a serum sample taken for other serologic studies, from October 1 to November 30, 2019 (before the first cases of COVID-19 were reported). Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analysis was performed with SPSS v20.0 (IBM Corp., Armonk, NY, USA). SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open …
SciScore for 10.1101/2020.04.11.20062158: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization Population and study period: We included three groups of patients in our study: Group 1 (healthy controls): a randomly selected group of 55 patients who had a serum sample taken for other serologic studies, from October 1 to November 30, 2019 (before the first cases of COVID-19 were reported). Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analysis was performed with SPSS v20.0 (IBM Corp., Armonk, NY, USA). SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study is subject to some limitations. First, it has been conducted in a single hospital. Further multicenter studies are necessary to reinforce our findings. Second, patient selection was made according to the diagnostic needs of our hospital. Consequently, group 3 patients were all patients with negative PCR patients with clinical and radiological criteria of pneumonia and because of that, our results could not be generalized to other patients with COVID-19 and other clinical syndromes. Additionally, group 3 patients also presented a longer evolution time than group 2 patients. This probably explains that the overall positivity rates of the serological test are better than in group 3 (88.9% vs 47.3% in group 2). However, when we focus on patients with 14 or more days from onset of symptoms, the sensitivity and positivity rate increased for groups (91.1% for group 3 and 73.9% for group 2 patients). Because all of these limitations, further studies including all kinds of clinical presentations are needed in order to reinforce our conclusions. The question about the reliability of serologic rapid tests is still under debate (18,19) and more research is needed on this topic. We think that our study may help to point out the usefulness of these rapid tests.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-